SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110

This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment

SciSparc shares are trading higher after the company announced its subsidiary, NeuroThera labs, continued advancement in participant enrollment for the clinical trial assessing the SCI-210 treatment for symptoms associated with autism spectrum disorder

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI marketTEL AVIV, Israel, Aug. 26, 2026 (GLOBE

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financingTEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)

SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel